89bio Inc (NASDAQ:ETNB) — Market Cap & Net Worth
Market Cap & Net Worth: 89bio Inc (ETNB)
89bio Inc (NASDAQ:ETNB) has a market capitalization of $2.20 Billion ($2.20 Billion) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5766 globally and #1875 in its home market, demonstrating a 0.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 89bio Inc's stock price $14.84 by its total outstanding shares 148492428 (148.49 Million). Review ETNB liabilities breakdown to assess the company's total debt and financial obligations.
89bio Inc Market Cap History: 2019 to 2025
89bio Inc's market capitalization history from 2019 to 2025. Data shows change from $3.90 Billion to $2.20 Billion (-5.50% CAGR).
Index Memberships
89bio Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.09% | #150 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.01% | #660 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.13% | #94 of 263 |
Weight: 89bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
89bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 89bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ETNB by Market Capitalization
Companies near 89bio Inc in the global market cap rankings as of August 3, 2026.
Key companies related to 89bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
89bio Inc Historical Marketcap From 2019 to 2025
Between 2019 and today, 89bio Inc's market cap moved from $3.90 Billion to $ 2.20 Billion, with a yearly change of -5.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.20 Billion | +89.77% |
| 2024 | $1.16 Billion | -29.99% |
| 2023 | $1.66 Billion | -12.25% |
| 2022 | $1.89 Billion | -2.60% |
| 2021 | $1.94 Billion | -46.37% |
| 2020 | $3.62 Billion | -7.30% |
| 2019 | $3.90 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of 89bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.20 Billion USD |
| MoneyControl | $2.20 Billion USD |
| MarketWatch | $2.20 Billion USD |
| marketcap.company | $2.20 Billion USD |
| Reuters | $2.20 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly kn… Read more